Embla Medical (EMBLA) Q4 2024 earnings summary

Executive summary

• Achieved 6% organic sales growth for the full year, with strong performance in EMEA and Prosthetics, Neuro-Orthotics, and Patient Care segments.

• Launched innovative bionic knee products (ICON and NAVII/Navii®) and expanded U.S. Medicare coverage for advanced prosthetics, including K2 patients.

• Completed the acquisition of Fior & Gentz, expanding into neuro-orthotics and rolling out products in the U.S., France, Switzerland, and EMEA.

• Rebranded patient care facilities under the ForMotion brand, with ongoing rollout and completion expected in 2025.

• Strong cash flow and profitability, with a new share buyback program to be initiated as leverage returns to target range.

Financial highlights

• Full-year organic sales growth of 6% and local currency growth of 9% including Fior & Gentz acquisition; Q4 organic sales growth at 5%.

• EBITDA margin before special items at 21% for Q4 and 20% for the full year, up 2-3 percentage points year-over-year.

• Gross profit margin reached 63% in Q4 and FY 2024, up from 61-62% in 2023, driven by cost reductions and product mix.

• Net profit for the year grew 17% to USD 69 million, or 8% of sales.

• Free cash flow in Q4 was USD 34 million (15% of sales); full-year free cash flow was 9% of sales.

Outlook and guidance

• 2025 guidance: 5%-8% organic sales growth and 20%-21% EBITDA margin before special items.

• Growth expected from new bionic knee launches, expanded Medicare coverage, and continued rollout of neuro-orthotics.

• CAPEX expected at 3-4% of sales; effective tax rate projected at 23-24%.

• FX impact expected to be neutral; potential U.S. trade tariffs not yet reflected in guidance.